You are here

New Insulin Delivery Device Launched in U.S.

Levemir FlexTouch contains insulin detemir

A new prefilled insulin delivery device, Levemir FlexTouch (insulin detemir [rDNA origin] injection), is now available in the U.S.

According to the product’s manufacturer (Novo Nordisk), when a dose is dialed with traditional prefilled insulin pens, the push button extends, and at larger doses this may present delivery challenges for the patient. Levemir FlexTouch is the first prefilled insulin delivery device with no push-button extension.

The prefilled pen contains 300 units of insulin detemir. The pen doses in one-unit increments, from one to 80 units, and is compatible with both NovoFine and the latest NovoTwist needles.

Levemir FlexTouch was approved by the FDA in November 2013. The device is available on more than 96% of commercial and Medicare Part D plans nationwide, including exclusive tier 1 status on UnitedHealthcare and preferred status on Coventry.

Source: Novo Nordisk; June 19, 2014.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs